Sefunda, is a small dedicated team of professionals with a background in IVD product development, molecular epidemiology, medical device development, and material science combined with business strategy. Sefunda is funded by seed investors.
Sefunda AG, a Swiss-based company (04/23/2019) with their headquarter in the city of Muttenz and with its Sefunda LLC (Invest/Co. - 05/28/2021) in Wilmington / Delaware, is looking to raise $6,000,000 USD via Equity Crowdfunding.
THE CONCEPT: - A Real-Time Diagnostics Platform
Through our rapid, lean and accessible testing platform we make patient-tailored treatment truly accessible and affordable for everybody – delivering immediate actionable results for treatment decision within one single visit. By combining robust, proven, and adaptable technology with smart multiplexing capabilities, we bring the precision of a molecular diagnostics lab to your office
THE START:: - Chlamydia and Gonorrhea are the most common notifiable infectious diseases* in the US.
Both Chlamydia and Gonorrhea can cause severe reproductive complications and co-infection can lead to a higher transmission rate of HIV. Rapid detection and prompt treatment of patients and partners are detrimental to prevent spreading. Cephalosporin-resistant N. gonorrhea is often resistant to multiple classes of antibiotics and is likely to fail empiric treatment. Today the percentage of these strains worldwide hovers around 30% and leaves plenty of leverage for a safe treatment with cephalosporins like Ciprofloxacin. However, current guidelines precautionary recommend a dual antibiotic treatment including an injectable drug which represents the last treatment option. As strains resistant to this last-resort treatment have already emerged, it is only a matter of time until they take over and render some Gonorrhoeae infections untreatable.
Rapid detection of a curated set of antimicrobial-resistant markers can help decide which treatment is safe, effective and has the potential to spare valuable last-line treatment options to help delay the spread of untreatable pan-resistant N. gonorrhea. (*Chlamydia >1.8 million cases p. a.; Gonorrhoeae > 0.5 million cases p. a.).